Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBX13-ADC
- Development stage
- Preclinical
- Lead developer
- Ibex Biosciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IBX13-ADC is an antibody-drug conjugate (ADC) developed by Ibex Biosciences. As an ADC, it consists of a monoclonal antibody linked to a cytotoxic chemotherapy payload via a chemical linker. The antibody component targets specific antigens on the surface of cancer cells, allowing for targeted delivery of the cytotoxic agent directly into malignant cells while minimizing damage to healthy tissue. This approach aims to improve efficacy and reduce systemic toxicity compared to conventional chemotherapy. IBX13-ADC is being investigated primarily for the treatment of neoplasms, with colonic cancer as its lead indication[1]. As of May 2025, its highest development status is preclinical[1].
- Other names
- IBX13 ADCIBX-13 ADCIBX 13 ADC
Beyond the preview
Go deeper on IBX13-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBX13-ADC.